Neurobixin (Benfotiamine, Pyridoxine Hydrochloride)

Benfotiamine is a lipid‑soluble form of thiamine that raises intracellular thiamine diphosphate levels. This enhances the activity of the enzyme transketolase, helping to divert harmful glucose metabolites away from pathways that generate advanced glycation end‑products, thereby protecting nerves and supporting metabolic balance.

The appropriate dose of Neurobixin is determined by the prescribing healthcare professional based on the individual’s condition, age, and overall health. Patients should follow the prescriber’s instructions and not adjust the dose on their own.

Safety data for Neurobixin in pregnancy and lactation are limited. It should be used only if the prescriber judges that the potential benefit outweighs any possible risk to the fetus or infant. Women who are pregnant or breastfeeding should discuss use with their healthcare provider.

To order Neurobixin, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Neurobixin uniquely combines benfotiamine, a thiamine derivative with strong evidence for reducing advanced glycation end‑products, and pyridoxine, a vitamin B6 source essential for neurotransmitter synthesis. Many other supplements contain only one of these vitamins, so Neurobixin offers a broader metabolic and neuroprotective profile.

Neurobixin should be stored at ambient temperature, below 25 °C. Keep the product in its original packaging, protect it from moisture and direct sunlight, and ensure the container is tightly closed to maintain stability.

Neurobixin is taken orally, usually with water. The tablet or capsule should be swallowed whole and not chewed or crushed unless the prescriber advises otherwise. It can be taken with or without food, depending on individual tolerance.

Serious risks, though rare, include severe allergic reactions such as anaphylaxis, significant skin eruptions, and possible liver enzyme elevations. Patients should seek immediate medical attention if they experience swelling, difficulty breathing, rash, or unexplained jaundice.

Neurobixin should be avoided by individuals with known hypersensitivity to benfotiamine, pyridoxine, or any excipients in the formulation. It is also not recommended for patients with severe renal impairment unless specifically directed by a healthcare professional.